Analysts Set uniQure (NASDAQ:QURE) Price Target at $32.14

Shares of uniQure (NASDAQ:QURE) have been assigned a consensus rating of “Buy” from the ten brokerages that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $32.13.

A number of brokerages have commented on QURE. StockNews.com upgraded uniQure to a “sell” rating in a research report on Wednesday, December 11th. Wells Fargo & Company raised shares of uniQure from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 10th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of uniQure in a report on Tuesday, December 10th. Stifel Nicolaus increased their price objective on shares of uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Leerink Partners raised their price objective on shares of uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a research report on Wednesday, December 11th.

uniQure Price Performance

NASDAQ QURE opened at $16.46 on Friday. The company has a 50-day moving average price of $7.28 and a 200-day moving average price of $6.47. uniQure has a 52 week low of $3.73 and a 52 week high of $17.71. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The firm has a market capitalization of $802.31 million, a P/E ratio of -3.27 and a beta of 0.89.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The company had revenue of $2.29 million during the quarter, compared to analyst estimates of $2.73 million. Equities research analysts anticipate that uniQure will post -3.82 earnings per share for the current year.

Insider Transactions at uniQure

In related news, CEO Matthew C. Kapusta sold 3,418 shares of the business’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the sale, the chief executive officer now directly owns 597,915 shares in the company, valued at approximately $4,562,091.45. The trade was a 0.57 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.74% of the company’s stock.

Institutional Trading of uniQure

A number of large investors have recently added to or reduced their stakes in QURE. RTW Investments LP purchased a new position in shares of uniQure in the third quarter valued at $49,000. China Universal Asset Management Co. Ltd. lifted its position in uniQure by 57.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 3,663 shares during the last quarter. Atria Investments Inc purchased a new position in shares of uniQure in the 3rd quarter worth $53,000. Quarry LP bought a new stake in shares of uniQure in the 3rd quarter worth about $58,000. Finally, Vanguard Personalized Indexing Management LLC increased its holdings in shares of uniQure by 21.0% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after buying an additional 2,306 shares during the last quarter. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.